The doctors take on two of the topics their followers ask about most, giving their verdict on statins and Ozempic.
Recap by typeshit. Post by @thebraindocs on Instagram.
CNBC's investing team lifts its target on Lilly shares and argues the obesity drug run still has room to grow.
The Pharma Letter looks at how semaglutide generics are changing strategy in India, with Torrent eyeing an expansion into Brazil.
Semafor looks at how little national political figures have said about what the new class of weight loss drugs means for policy.
Social media promoters claim peptides speed healing, smooth skin and extend life, and CBS notes the HHS Secretary counts himself a fan.
Law firm Frier Levitt reads the rule as single-ingredient only, so the popular blend stays out. Public Citizen and ex-FDA official Janet Woodcock voice safety concerns.
She sorts skincare peptides into three main groups, starting with signalling peptides that she says prompt more collagen production.
Loading…